

Received: from CEXMB001.nmes.lcl ([fe80::6cb4:be40:8604:bdc9]) by
CEXHUB003.nmes.lcl (:::1) with mapi id 14.03.0224.002; Tue, 12 May 2015
10:02:57 -0600
From: "Landen, Michael, DOH" <Michael.Landen@state.nm.us>
To: "Kesner, Ben., RLD" <Ben.Kesner@state.nm.us>
Subject: RE: Naloxone
Thread-Topic: Naloxone
Thread-Index:
AdCEShoFyjBNlfsFTIS8MAP3e/1j1gA0UGKAAg68BhAAA2nNYAAAJ0VwAAANqQAAABBBckA==
Date: Tue, 12 May 2015 16:02:55 +0000
Message-ID: <599333538BEA184180E0846B03FAE6B1FAA48369@CEXMB001.nmes.lcl>
References: <599333538BEA184180E0846B03FAE6B1FAA37671@CEXMB001.nmes.lcl>
<B6049650E7BD8D44A97BBD23BBC9E54526843AA4@CEXMB003.nmes.lcl>
<599333538BEA184180E0846B03FAE6B1FAA47D8E@CEXMB001.nmes.lcl>
<B6049650E7BD8D44A97BBD23BBC9E5452684B411@CEXMB003.nmes.lcl>
<599333538BEA184180E0846B03FAE6B1FAA48330@CEXMB001.nmes.lcl>
<B6049650E7BD8D44A97BBD23BBC9E5452684B430@CEXMB003.nmes.lcl>
In-Reply-To: <B6049650E7BD8D44A97BBD23BBC9E5452684B430@CEXMB003.nmes.lcl>
Accept-Language: en-US
Content-Language: en-US
X-MS-Exchange-Organization-AuthMechanism: 04
X-MS-Exchange-Organization-AuthSource: CEXHUB003.nmes.lcl
X-MS-Has-Attach:
X-MS-Exchange-Organization-SCL: -1
X-MS-TNEF-Correlator:
Content-Type: multipart/alternative;
boundary="_000_599333538BEA184180E0846B03FAE6B1FAA48369CEXMB001nmeslcl_"
MIME-Version: 1.0

--_000_599333538BEA184180E0846B03FAE6B1FAA48369CEXMB001nmeslcl_
Content-Type: text/plain; charset="us-ascii"
Content-Transfer-Encoding: quoted-printable

Ben,

Thanks,

Mike

From: Kesner, Ben., RLD
Sent: Tuesday, May 12, 2015 10:01 AM
To: Landen, Michael, DOH
Subject: RE: Naloxone

The DOH did it for school based clinics. Allowing schools to have Albutero=
1 and Epinephrine.

Ben Kesner

Executive Director

Regulation and Licensing Department

New Mexico Board of Pharmacy

(505) 222-9838 - Office

(505) 222-9845 - Fax

ben.kesner@state.nm.us<mailto:ben.kesner@state.nm.us>

www.rld.state.nm.us/pharmacy<http://www.rld.state.nm.us/pharmacy>

REPORT CHILD ABUSE OR NEGLECT # SAFE (#7233) from a cell phone or 1-855-33-3-SAFE .

Confidentiality Notice: This e-mail, including all attachments is for the sole use of the intended recipient[s] and may contain confidential and/or privileged information. Any unauthorized use, copying, disclosure or distribution is prohibited, unless specifically provided under New Mexico Inspection of Public Records Act. If you are not the intended recipient, please contact the sender at once and destroy all copies of this message.

From: Landen, Michael, DOH
Sent: Tuesday, May 12, 2015 10:00 AM
To: Kesner, Ben., RLD
Subject: RE: Naloxone

Ben,

That would be great - so NM could do this on its own without FDA regulatory change?

Thanks,

MIke

From: Kesner, Ben., RLD
Sent: Tuesday, May 12, 2015 9:58 AM
To: Landen, Michael, DOH
Subject: RE: Naloxone

Hi Mike,

I think this would work. But it would take a statutory change.

If you could do this, that would be good.

Thanks, Ben

Ben Kesner

Executive Director

Regulation and Licensing Department

New Mexico Board of Pharmacy

(505) 222-9838 - Office

(505) 222-9845 - Fax

ben.kesner@state.nm.us<<mailto:ben.kesner@state.nm.us>>

www.rld.state.nm.us/pharmacy<<http://www.rld.state.nm.us/pharmacy>>

REPORT CHILD ABUSE OR NEGLECT # SAFE (#7233) from a cell phone or 1-855-33-3-SAFE .

Confidentiality Notice: This e-mail, including all attachments is for the sole use of the intended recipient[s] and may contain confidential and/or privileged information. Any unauthorized use, copying, disclosure or distribution is prohibited, unless specifically provided under New Mexico Inspection of Public Records Act. If you are not the intended recipient, please contact the sender at once and destroy all copies of this message.

From: Landen, Michael, DOH
Sent: Tuesday, May 12, 2015 8:19 AM
To: Kesner, Ben., RLD
Subject: RE: Naloxone

Ben,

Thanks for a good meeting Thursday.

A quick question - if a NM law was passed moving naloxone to behind the counter would this be allowable if FDA did not change naloxone's status.

Mike

From: Kesner, Ben., RLD
Sent: Friday, May 01, 2015 9:00 PM
To: Landen, Michael, DOH
Subject: RE: Naloxone

Hi Mike,

Tuesday or Wednesday look OK next week.

Please let me know available days or times and I will try to make myself available.

If you would like any NMBOP staff to be available, I can arrange for that also.

Thank you, Ben

Ben Kesner

Executive Director

Regulation and Licensing Department

New Mexico Board of Pharmacy

(505) 222-9838 - Office

(505) 222-9845 - Fax

ben.kesner@state.nm.us<<mailto:ben.kesner@state.nm.us>>

www.rld.state.nm.us/pharmacy<<http://www.rld.state.nm.us/pharmacy>>

REPORT CHILD ABUSE OR NEGLECT # SAFE (#7233) from a cell phone or 1-855-333-SAFE .

Confidentiality Notice: This e-mail, including all attachments is for the sole use of the intended recipient[s] and may contain confidential and/or privileged information. Any unauthorized use, copying, disclosure or distribution is prohibited, unless specifically provided under New Mexico Inspection of Public Records Act. If you are not the intended recipient, please contact the sender at once and destroy all copies of this message.

From: Landen, Michael, DOH
Sent: Friday, May 01, 2015 2:07 PM
To: Kesner, Ben., RLD
Subject: Naloxone

Ben,

Some of us from DOH wanted to discuss with you use of naloxone by DOH and contractors for about an hour. Could you let me know a couple of times that would work for you for a meeting at your place?

Thanks,

Mike

Michael Landen, MD, MPH
State Epidemiologist
New Mexico Department of Health

--_000_599333538BEA184180E0846B03FAE6B1FAA48369CEXMB001nmeslcl_
Content-Type: text/html; charset="us-ascii"
Content-Transfer-Encoding: quoted-printable

```
<html xmlns:v=3D"urn:schemas-microsoft-com:vml" xmlns:o=3D"urn:schemas-microsoft-com:office:office" xmlns:w=3D"urn:schemas-microsoft-com:office:word" xmlns:m=3D"http://schemas.microsoft.com/office/2004/12/omml" xmlns=3D"http://www.w3.org/TR/REC-html40">
<head>
<meta http-equiv=3D"Content-Type" content=3D"text/html; charset=3Dus-ascii">
<meta name=3D"Generator" content=3D"Microsoft Word 15 (filtered medium)">
<style><!--
/* Font Definitions */
```

```

@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:Tahoma;
panose-1:2 11 6 4 3 5 4 4 2 4;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0in;
margin-bottom:.0001pt;
font-size:11.0pt;
font-family:"Calibri","sans-serif";}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:#0563C1;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:#954F72;
text-decoration:underline;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
{mso-style-priority:99;
mso-style-link:"Balloon Text Char";
margin:0in;
margin-bottom:.0001pt;
font-size:8.0pt;
font-family:"Tahoma","sans-serif";}
span.BalloonTextChar
{mso-style-name:"Balloon Text Char";
mso-style-priority:99;
mso-style-link:"Balloon Text";
font-family:"Tahoma","sans-serif";}
span.EmailStyle19
{mso-style-type:personal;
font-family:"Calibri","sans-serif";
color:windowtext;}
span.EmailStyle20
{mso-style-type:personal;
font-family:"Calibri","sans-serif";
color:#1F497D;}
span.EmailStyle21
{mso-style-type:personal;
font-family:"Calibri","sans-serif";
color:#1F497D;}
span.EmailStyle22
{mso-style-type:personal;
font-family:"Calibri","sans-serif";
color:#1F497D;}
span.EmailStyle23
{mso-style-type:personal;
font-family:"Calibri","sans-serif";
color:#1F497D;}
span.EmailStyle24
{mso-style-type:personal;
font-family:"Calibri","sans-serif";
color:#1F497D;}

```

span.EmailStyle25
{mso-style-type:personal-reply;
font-family:"Calibri","sans-serif";
color:#1F497D;}

.MsoChpDefault
{mso-style-type:export-only;
font-size:10.0pt;}

@page WordSection1
{size:8.5in 11.0in;
margin:1.0in 1.0in 1.0in 1.0in;}

div.WordSection1
{page:WordSection1;}

--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext=3D"edit" spidmax=3D"1026" />
</xml><![endif]><!--[if gte mso 9]><xml>
<o:shapelayout v:ext=3D"edit">
<o:idmap v:ext=3D"edit" data=3D"1" />
</o:shapelayout></xml><![endif]>-->
</head>
<body lang=3D"EN-US" link=3D"#0563C1" vlink=3D"#954F72">
<div class=3D"WordSection1">
<p class=3D"MsoNormal">Ben,<o:p></o:p>=</p>
<p class=3D"MsoNormal"><o:p> </o:p>=</p>
<p class=3D"MsoNormal">Thanks,<o:p></o:p>=</p>
<p class=3D"MsoNormal"><o:p> </o:p>=</p>
<p class=3D"MsoNormal">Mike<o:p></o:p>=</p>
<p class=3D"MsoNormal"><o:p> </o:p>=</p>
<div>
<div style=3D"border:none;border-top:solid #E1E1E1 1.0pt;padding:3.0pt 0in = 0in 0in">
<p class=3D"MsoNormal">From: Kesner, Ben., RLD

Sent: Tuesday, May 12, 2015 10:01 AM

To: Landen, Michael, DOH

Subject: RE: Naloxone<o:p></o:p></p>
</div>
</div>
<p class=3D"MsoNormal"><o:p> </o:p></p>
<p class=3D"MsoNormal"><o:p> </o:p></p>
<p class=3D"MsoNormal"><o:p> </o:p>=</p>
<div>
<p class=3D"MsoNormal">Ben Kesner<o:p></o:p></p>
<p class=3D"MsoNormal">Executive Director<o:p></o:p></p>
<p class=3D"MsoNormal">Regulation and Licensi= ng Department<o:p></o:p></p>
<p class=3D"MsoNormal">New Mexico Board of Ph= armacy<o:p></o:p></p>
<p class=3D"MsoNormal">(505) 222-9838 - Offic= e<o:p></o:p></p>

(505) 222-9845 - Fax

ben.kesner@state.nm.us

www.rld.state.nm.us/pharmacy/

REPORT CHILD ABUSE OR NEGLECT

SAFE (#7233) from a cell phone or 1-855-333-SAFE .

Confidentiality Notice:

This e-mail, including all attachments is for the sole use of the intended recipient[s] and may contain confidential and/or privileged information. Any unauthorized use, copying, disclosure or distribution is prohibited, unless specifically provided under New Mexico Inspection of Public Records Act.

If you are not the intended recipient, please contact the sender at once and destroy all copies of this message.

From: Landen, Michael, DOH

Sent: Tuesday, May 12, 2015 10:00 AM

To: Kesner, Ben., RLD

Subject: RE: Naloxone

Ben,

That would be great – so NM could do this on its own without FDA regulatory change?

Thanks,

n></p>
<p class=3D"MsoNormal">Mike <o:p></o:p>
></p>
<p class=3D"MsoNormal"><o:p> </o:p></spa>
n></p>
<div>
<div style=3D"border:none;border-top:solid #E1E1E1 1.0pt;padding:3.0pt 0in =
0in 0in">
<p class=3D"MsoNormal">From: Kesner, Ben., RLD

Sent: Tuesday, May 12, 2015 9:58 AM

To: Landen, Michael, DOH

Subject: RE: Naloxone<o:p></o:p></p>
</div>
</div>
<p class=3D"MsoNormal"><o:p> </o:p></p>
<p class=3D"MsoNormal">Hi Mike,<o:p></o:p></s>
pan></p>
<p class=3D"MsoNormal"><o:p> </o:p></spa>
n></p>
<p class=3D"MsoNormal">I think this would wor<=br>k. </p>
<p class=3D"MsoNormal">If you could do this, =
that would be good.<o:p></o:p></p>
<p class=3D"MsoNormal"><o:p> </o:p></spa>
n></p>
<p class=3D"MsoNormal">Thanks, Ben<o:p></o:p>=</p>
<p class=3D"MsoNormal"><o:p> </o:p></spa>
n></p>
<div>
<p class=3D"MsoNormal">Ben Kesner<o:p></o:p><=</p>
<p class=3D"MsoNormal">Executive Director<o:p></o:p></p>
<p class=3D"MsoNormal">Regulation and Licensi<=br>ng Department<o:p></o:p></p>
<p class=3D"MsoNormal">New Mexico Board of Ph<=br>armacy<o:p></o:p></p>
<p class=3D"MsoNormal">(505) 222-9838 - Offic<=br>e<o:p></o:p></p>
<p class=3D"MsoNormal">(505) 222-9845 - Fax<o<=br>:p></o:p></p>
<p class=3D"MsoNormal"><a href=3D"mailto:ben.<=br>kesner@state.nm.us">ben.kesner@state.nm.us<o:p></o:p></p>
<p class=3D"MsoNormal"><a href=3D"http://www.<=br>rld.state.nm.us/pharmacy">www.rld.state.nm.us/ph<=br>armacy<o:p></o:p></p>
<p class=3D"MsoNormal"><o:p> </o:p></spa>
n></p>
<p class=3D"MsoNormal">REPOR<=br>T CHILD ABUSE OR NEGLECT
SAFE (#7233) from a cell phone or 1-855-333-SAFE .<=br>/span><span style=3D"font-size:10.0pt;font-family:"Arial";"=<=br>t;sans-serif";color:#1F497D"><o:p></o:p></p>
<p class=3D"MsoNormal"><span style=3D"font-size:10.0pt;font-family:"=<=br>;Arial";"sans-serif";color:#1F497D"><o:p> </o:p>=</p>
<p class=3D"MsoNormal"><span style=3D"font-size:10.0pt;font-family:"=<=br>;Arial";"sans-serif";color:#1F497D"><o:p> </o:p>=</p>

Confidentiality Notice: This e-mail, including all attachments is

for the sole use of the intended recipient[s] and may contain confidential and/or privileged information. Any unauthorized use, copying, disclosure or distribution is prohibited, unless specifically provided under New Mexico Inspection of Public Records Act.

If you are not the intended recipient, please contact the sender at once and destroy all copies of this message.

From: Landen, Michael, DOH

Sent: Tuesday, May 12, 2015 8:19 AM

To: Kesner, Ben., RLD

Subject: RE: Naloxone

Ben,

Thanks for a good meeting Thursday.

A quick question; if a NM law was passed moving naloxone to behind the counter would this be allowable if FDA did not change naloxone's status.

Mike

From: Kesner, Ben., RLD

Sent: Friday, May 01, 2015 9:00 PM

To: Landen, Michael, DOH

Subject: RE: Naloxone

Hi Mike,

n></p>
<p class=3D"MsoNormal">Tuesday or Wednesday I look OK next week.</p>
<p class=3D"MsoNormal">Please let me know available days or times and I will try to make myself available.</p>
<p class=3D"MsoNormal">If you would like any NMBOP staff to be available, I can arrange for that also.</p>
<p class=3D"MsoNormal"><p> </p></p>
<p class=3D"MsoNormal">Thank you, Ben</p>
<p class=3D"MsoNormal"><p> </p></p>
<div>
<p class=3D"MsoNormal">Ben Kesner</p>
<p class=3D"MsoNormal">Executive Director</p>
<p class=3D"MsoNormal">Regulation and Licensing Department</p>
<p class=3D"MsoNormal">New Mexico Board of Pharmacy</p>
<p class=3D"MsoNormal">(505) 222-9838 - Office</p>
<p class=3D"MsoNormal">(505) 222-9845 - Fax</p>
<p class=3D"MsoNormal">ben.kesner@state.nm.us</p>
<p class=3D"MsoNormal">www.rld.state.nm.us/pharmacy</p>
<p class=3D"MsoNormal"><p> </p></p>
<p class=3D"MsoNormal">REPORT CHILD ABUSE OR NEGLECT
SAFE (#7233) from a cell phone or 1-855-333-SAFE .<p></p></p>
<p class=3D"MsoNormal"><p> </p></p>
<p class=3D"MsoNormal">Confidentiality Notice: This e-mail, including all attachments is
for the sole use of the intended recipient[s] and may contain confidential and/or privileged information. Any unauthorized use, copying, disclosure or distribution is prohibited, unless specifically provided under New Mexico Inspection of Public Records Act.
If you are not the intended recipient, please contact the sender at once and destroy all copies of this message.<p></p></div>
<p class=3D"MsoNormal"><p> </p></p>

<div>
<div style=3D"border:none;border-top:solid #B5C4DF 1.0pt;padding:3.0pt 0in =
0in 0in">
<p class=3D"MsoNormal"><span style=3D"font-size:10.0pt;font-family:"=
;Tahoma";"sans-serif"">From:<span style=3D"font-s=
ize:10.0pt;font-family:"Tahoma";"sans-serif""> Landen, =
Michael, DOH

Sent: Friday, May 01, 2015 2:07 PM

To: Kesner, Ben., RLD

Subject: Naloxone<o:p></o:p></p>
</div>
</div>
<p class=3D"MsoNormal"><o:p> </o:p></p>
<p class=3D"MsoNormal">Ben,<o:p></o:p></p>
<p class=3D"MsoNormal"><o:p> </o:p></p>
<p class=3D"MsoNormal">Some of us from DOH wanted to discuss with you use o=
f naloxone by DOH and contractors for about an hour. Could you let me know =
a couple of times that would work for you for a meeting at your place?<o:p>=
</o:p></p>
<p class=3D"MsoNormal"><o:p> </o:p></p>
<p class=3D"MsoNormal">Thanks,<o:p></o:p></p>
<p class=3D"MsoNormal"><o:p> </o:p></p>
<p class=3D"MsoNormal">Mike<o:p></o:p></p>
<p class=3D"MsoNormal"><o:p> </o:p></p>
<p class=3D"MsoNormal"><o:p> </o:p></p>
<p class=3D"MsoNormal">Michael Landen, MD, MPH<o:p></o:p></p>
<p class=3D"MsoNormal">State Epidemiologist<o:p></o:p></p>
<p class=3D"MsoNormal">New Mexico Department of Health <o:p></o:p></p>
>
</div>
</body>
</html>

--_000_599333538BEA184180E0846B03FAE6B1FAA48369CEXMB001nmeslcl_--